Life sciences company Abcam initiated the construction of its new global headquarters building at the Cambridge Biomedical Campus (CBC) in Cambridge, UK, in June 2017.
The new research and development facility and corporate headquarters is intended to accommodate the company’s UK research, development and manufacturing capabilities, as well as laboratories, marketing, sales, logistics, and corporate activities.
The site is expected to be opened by the end of 2018 and will accommodate up to 450 employees, which is approximately half of the company’s global employee base.
Abcam’s new state-of-the-art Grade A headquarters will comprise a total floor space of roughly 100,000ft², and is set to combine the company’s three existing facilities at the Cambridge Science Park, UK, which feature a combined footprint of 38,851ft².
The new facility will also feature a four-storey, 60,000ft² building to house office and welfare facilities, and a three-storey research and laboratory building.
The office building incorporates a meeting room, working space, and a fourth-floor plant room.
Its laboratory and office buildings will be linked to each other via a glazed atrium.
The research and laboratory building will be built on an area of approximately 40,000ft² for the production of biochemicals, lysates, primary and secondary antibodies, peptides, proteins, immunoassays, and other life science research tools.
In addition, the laboratory will be used for the research and development of new products, which are to be distributed to third parties for use in clinical and biotech research.
Abcam’s new global headquarters building is part of the 20-acre phase two expansion of the CBC, which is situated two miles south of the Cambridge City Centre.
CBC’s phase two expansion is being developed by a joint venture between Liberty Property Trust and Countryside Properties known as Cambridge Medipark.
Abcam signed an agreement with Liberty Property Trust and Countryside Properties to lease 100,000ft² of facility in October 2016.
The company also executed a pre-let contract with the site developers in March 201,7 which will see new facility leased for a period of 20 years at a rate of £3.03m ($3.85m) a year.
Tesco Pension Fund agreed to provide forward funding for the site, which is the first to be built as part of the second phase expansion.
The global headquarters building is expected to help Abcam to enhance discovery in the fields of life sciences and clinical innovation.
It is anticipated to improve the company’s product development and innovation capabilities, in order to meet the requirements of the global research communities in biomedical and biotechnology.
The new site will also strengthen the company’s ability to provide reagents and tools for the research and clinical communities.
Additionally, the facility will enable greater interaction between the firm’s marketing and selling teams, and scientists, to improve Abcam’s presence in the UK market.
It will also serve as the company’s distribution centre in Europe.
US-based architecture, planning and design firm NBBJ was appointed to design Abcam’s new purpose-built office and laboratory facility.
Kier Group, a provider of property, residential, construction and services based in the UK, secured a deal to build the facility in March 2017.
UK-based company APS was contracted to provide technical and financial advisory services for the design and development of the new Abcam site.
The Columbus Innovation District is a proposed healthcare and technology hub within the Ohio State University in the state of…
Rocket Pharmaceuticals will build a new research and development (R&D) and manufacturing facility in Cranbury, New Jersey, US to support…
BioNTech’s manufacturing site in Marburg, Germany, will be used for the production of its Covid-19 vaccine candidate, BNT162. Based on…